Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CYTOKINETICS INC Director's Dealing 2025

Mar 18, 2025

30870_dirs_2025-03-17_89e3e831-e267-4d29-ae31-3686a5deba89.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2025-03-17

Reporting Person: Callos Andrew (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-03-17 Common Stock S 2775 $44.38 Disposed 34888 Direct

Footnotes

F1: Sell to cover transaction in connection with the vesting of restricted stock units.